Drug Interactions With New Synthetic Opioids

Fentanyl, fentanyl analogs, and other new synthetic opioids (NSO) have burst onto the illegal drug market as new psychoactive substances (NPS). They are often sold as heroin to unsuspecting users and produce euphoria through their agonist action on μ- opioid receptors. Their high consumption, often combined with other substances, has led to multiple intoxications during recent years. In some countries, such as the United States, the consumption of opioids, whether for medical or recreational purposes, has become epidemic and is considered a public health problem. Fentanyl analogs are more potent than fentanyl which in turn is 50 times more potent than morphine. Furthermore, some fentanyl analogs have longer duration of action and therefore interactions with other substances and medicines can be more serious. This review is focused on the potentially most frequent interactions of opioid NPS taking into account the drugs present in the reported cases of poly-intoxication, including other illegal drugs of abuse and medication. Substances involved are mainly antidepressants, antihistamines, antipsychotics, benzodiazepines, analgesics, anesthetics, psychostimulants, other opioids, alcohol, and illegal drugs of abuse. The interactions can be produced due to pharmacokinetic and pharmacodynamic mechanisms. Naloxone can be used as an antidote, although required doses might be higher than for traditional opioid intoxications. It is crucial that doctors who habitually prescribe opioids, which are often misused by patients and NPS users, be aware of designer opioids’ potentially life-threatening drug-drug interactions in order to prevent new cases of intoxication.

[1]  M. Barratt,et al.  Global Drug Survey , 2020 .

[2]  Stewart E. Glaspole Stockley’s Drug Interactions , 2018 .

[3]  R. Giorgetti,et al.  Pharmacotoxicology of Non-fentanyl Derived New Synthetic Opioids , 2018, Front. Pharmacol..

[4]  S. Schnoll Misconceptions and Realities of the Prescription Opioid Epidemic , 2018, Clinical pharmacology and therapeutics.

[5]  Blair H. Smith,et al.  Incidence of iatrogenic opioid dependence or abuse in patients with pain who were exposed to opioid analgesic therapy: a systematic review and meta‐analysis , 2018, British journal of anaesthesia.

[6]  Lawrence Scholl,et al.  Overdose deaths involving opioids, cocaine, and psychostimulants — United States, 2015–2016 , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[7]  B. Piper,et al.  Trends in Medical Use of Opioids in the U.S., 2006-2016. , 2018, American journal of preventive medicine.

[8]  S. Vosburg,et al.  Antagonists in the medical management of opioid use disorders: Historical and existing treatment strategies , 2018, The American journal on addictions.

[9]  N. Volkow,et al.  Medication development in opioid addiction: Meaningful clinical end points , 2018, Science Translational Medicine.

[10]  Y. Shaham,et al.  Fentanyl-Induced Brain Hypoxia Triggers Brain Hyperglycemia and Biphasic Changes in Brain Temperature , 2018, Neuropsychopharmacology.

[11]  M. Liechti,et al.  Opioid‐induced inhibition of the human 5‐HT and noradrenaline transporters in vitro: link to clinical reports of serotonin syndrome , 2018, British journal of pharmacology.

[12]  N. Volkow Medications for opioid use disorder: bridging the gap in care , 2017, The Lancet.

[13]  R. Pacifici,et al.  Acute Intoxications and Fatalities From Illicit Fentanyl and Analogues: An Update , 2017, Therapeutic drug monitoring.

[14]  J. Rehm,et al.  The 'fentanyl epidemic' in Canada - Some cautionary observations focusing on opioid-related mortality. , 2017, Preventive medicine.

[15]  Ya-Han Lee,et al.  Current Impact and Application of Abuse-Deterrent Opioid Formulations in Clinical Practice. , 2017, Pain physician.

[16]  R. Pacifici,et al.  European Drug Users at Risk from Illicit Fentanyls Mix , 2017, Front. Pharmacol..

[17]  Jill Barr-Walker,et al.  Fentanyl, fentanyl analogs and novel synthetic opioids: A comprehensive review , 2017, Neuropharmacology.

[18]  W. Hall,et al.  Trends in heroin and pharmaceutical opioid overdose deaths in Australia. , 2017, Drug and alcohol dependence.

[19]  T. Kerr,et al.  Chronic pain and opioid misuse: a review of reviews , 2017, Substance Abuse Treatment, Prevention, and Policy.

[20]  G. Pasternak,et al.  Pharmacological characterization of novel synthetic opioids (NSO) found in the recreational drug marketplace , 2017, Neuropharmacology.

[21]  F. Carvalho,et al.  Opioids in the Frame of New Psychoactive Substances Network: A Complex Pharmacological and Toxicological Issue. , 2017, Current molecular pharmacology.

[22]  T. Kraemer,et al.  Studies on the metabolism of the fentanyl-derived designer drug butyrfentanyl in human in vitro liver preparations and authentic human samples using liquid chromatography-high resolution mass spectrometry (LC-HRMS). , 2017, Drug testing and analysis.

[23]  J. Zawilska An Expanding World of Novel Psychoactive Substances: Opioids , 2017, Front. Psychiatry.

[24]  P. Mansky,et al.  Misuse of Novel Synthetic Opioids: A Deadly New Trend , 2017, Journal of addiction medicine.

[25]  D. Fiellin,et al.  Abuse-Deterrent Opioid Formulations - Putting the Potential Benefits into Perspective. , 2017, The New England journal of medicine.

[26]  N. Volkow,et al.  The Role of Science in Addressing the Opioid Crisis. , 2017, The New England journal of medicine.

[27]  Quan Zhou,et al.  Opioid analgesics-related pharmacokinetic drug interactions: from the perspectives of evidence based on randomized controlled trials and clinical risk management , 2017, Journal of pain research.

[28]  H. Gréen,et al.  In Vitro and In Vivo Metabolite Identification Studies for the New Synthetic Opioids Acetylfentanyl, Acrylfentanyl, Furanylfentanyl, and 4-Fluoro-Isobutyrylfentanyl , 2017, The AAPS Journal.

[29]  B. Martin,et al.  Characteristics of Initial Prescription Episodes and Likelihood of Long-Term Opioid Use — United States, 2006–2015 , 2017, MMWR. Morbidity and mortality weekly report.

[30]  Kunihiko Takahashi,et al.  Epidemiology of overdose episodes from the period prior to hospitalization for drug poisoning until discharge in Japan: An exploratory descriptive study using a nationwide claims database , 2017, Journal of epidemiology.

[31]  J. Suzuki,et al.  A review: Fentanyl and non-pharmaceutical fentanyls. , 2017, Drug and alcohol dependence.

[32]  D. Tracy,et al.  Novel psychoactive substances: types, mechanisms of action, and effects , 2017, British Medical Journal.

[33]  G. Janis,et al.  A case of U-47700 overdose with laboratory confirmation and metabolite identification , 2017, Clinical toxicology.

[34]  U. Garg,et al.  Analysis of U-47700, a Novel Synthetic Opioid, in Human Urine by LC-MS-MS and LC-QToF. , 2016, Journal of analytical toxicology.

[35]  Iain M McIntyre,et al.  A Fatality Related to the Synthetic Opioid U-47700: Postmortem Concentration Distribution. , 2016, Journal of analytical toxicology.

[36]  Y. Ohtsu,et al.  A fatal poisoning case by intravenous injection of "bath salts" containing acetyl fentanyl and 4-methoxy PV8. , 2016, Forensic science international.

[37]  B. Goldberger,et al.  Illicit Fentanyl-Related Fatalities in Florida: Toxicological Findings. , 2016, Journal of analytical toxicology.

[38]  M. Huestis,et al.  Metabolism of Carfentanil, an Ultra-Potent Opioid, in Human Liver Microsomes and Human Hepatocytes by High-Resolution Mass Spectrometry , 2016, The AAPS Journal.

[39]  Mingshe Zhu,et al.  Metabolic characterization of AH-7921, a synthetic opioid designer drug: in vitro metabolic stability assessment and metabolite identification, evaluation of in silico prediction, and in vivo confirmation. , 2016, Drug testing and analysis.

[40]  I. Takase,et al.  An autopsy case of acetyl fentanyl intoxication caused by insufflation of 'designer drugs'. , 2016, Legal medicine.

[41]  A. Kjellgren,et al.  The users of Novel Psychoactive Substances: Online survey about their characteristics, attitudes and motivations. , 2016, The International journal on drug policy.

[42]  I. Maremmani,et al.  Treatment Approaches for Patients With Opioid Use Disorder and Chronic Noncancer Pain: a Literature Review , 2016 .

[43]  R. Chou,et al.  CDC Guideline for Prescribing Opioids for Chronic Pain--United States, 2016. , 2016, JAMA.

[44]  J. Karalliedde,et al.  Adverse Drug Interactions : A Handbook for Prescribers, Second Edition , 2016 .

[45]  R. Chou,et al.  CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016. , 2016, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[46]  P. Griffiths,et al.  Fentanyls: Are we missing the signs? Highly potent and on the rise in Europe. , 2015, The International journal on drug policy.

[47]  Janet Brink The Misuse of Prescription Opioids: A Threat for Europe? , 2015 .

[48]  R. Chou,et al.  The Effectiveness and Risks of Long-Term Opioid Therapy for Chronic Pain: A Systematic Review for a National Institutes of Health Pathways to Prevention Workshop , 2015, Annals of Internal Medicine.

[49]  J. Mørland,et al.  Pharmacokinetic interactions between ethanol and heroin: a study on post-mortem cases. , 2014, Forensic science international.

[50]  R. Altman,et al.  PharmGKB summary: tramadol pathway. , 2014, Pharmacogenetics and genomics.

[51]  E. Sellers,et al.  Preventing and managing aberrant drug-related behavior in primary care: systematic review of outcomes evidence. , 2014, Journal of opioid management.

[52]  Laura D. Knight,et al.  Quantitative measurement of acetyl fentanyl and acetyl norfentanyl in human urine by LC-MS/MS. , 2014, Analytical chemistry.

[53]  M. Farré,et al.  Reacciones adversas de medicamentos relacionadas con el abuso y formas farmacéuticas disuasorias , 2013 .

[54]  J. Mørland,et al.  Levels of heroin and its metabolites in blood and brain extracellular fluid after i.v. heroin administration to freely moving rats , 2013, British journal of pharmacology.

[55]  J. Gudin Opioid therapies and cytochrome p450 interactions. , 2012, Journal of pain and symptom management.

[56]  R. de la Torre,et al.  MDMA, methamphetamine, and CYP2D6 pharmacogenetics: what is clinically relevant? , 2012, Front. Gene..

[57]  Edward W Boyer,et al.  Management of opioid analgesic overdose. , 2012, The New England journal of medicine.

[58]  Wesley T. Lindsey,et al.  Drug Interactions between Common Illicit Drugs and Prescription Therapies , 2012, The American journal of drug and alcohol abuse.

[59]  D. Foster,et al.  Opioid pharmacokinetic drug-drug interactions. , 2011, The American journal of managed care.

[60]  Monique L. Smith,et al.  Powerful behavioral interactions between methamphetamine and morphine , 2011, Pharmacology Biochemistry and Behavior.

[61]  E. Kharasch,et al.  Sensitivity of Intravenous and Oral Alfentanil and Pupillary Miosis as Minimal and Noninvasive Probes for Hepatic and First‐Pass CYP3A Induction , 2011, Clinical pharmacology and therapeutics.

[62]  D. Rybin,et al.  Identifying prescription opioid use disorder in primary care: Diagnostic characteristics of the Current Opioid Misuse Measure (COMM) , 2011, PAIN®.

[63]  R. Ferner Adverse Drug Interactions: A Handbook for Prescribers , 2011 .

[64]  S. Butler,et al.  Cross Validation of the Current Opioid Misuse Measure to Monitor Chronic Pain Patients on Opioid Therapy , 2010, The Clinical journal of pain.

[65]  R. Tyndale,et al.  Pharmacogenetics of drug dependence: role of gene variations in susceptibility and treatment. , 2010, Annual review of pharmacology and toxicology.

[66]  G. Tucker,et al.  The Consequences of 3,4-Methylenedioxymethamphetamine Induced CYP2D6 Inhibition in Humans , 2008, Journal of clinical psychopharmacology.

[67]  S. Butler,et al.  Validation of the revised Screener and Opioid Assessment for Patients with Pain (SOAPP-R). , 2008, The journal of pain : official journal of the American Pain Society.

[68]  Timothy A. Erickson,et al.  Fentanyl epidemic in Chicago, Illinois and surrounding Cook County , 2008, Clinical toxicology.

[69]  Gretchen M. Brophy Stockleyʼs Drug Interactions Pocket Companion , 2007 .

[70]  George S Behonick,et al.  Fatalities Associated with Fentanyl and Co‐administered Cocaine or Opiates , 2007, Journal of forensic sciences.

[71]  P. Shekelle,et al.  The addiction behaviors checklist: validation of a new clinician-based measure of inappropriate opioid use in chronic pain. , 2006, Journal of pain and symptom management.

[72]  L. Webster,et al.  Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool. , 2005, Pain medicine.

[73]  A. Polettini,et al.  The role of cocaine in heroin-related deaths. Hypothesis on the interaction between heroin and cocaine. , 2005, Forensic science international.

[74]  E. Kharasch,et al.  METABOLISM OF ALFENTANIL BY CYTOCHROME P4503A (CYP3A) ENZYMES , 2005, Drug Metabolism and Disposition.

[75]  Ruth E. Winecker,et al.  Fatal intravenous fentanyl abuse: four cases involving extraction of fentanyl from transdermal patches. , 2004, The American journal of forensic medicine and pathology.

[76]  A. J. Clark,et al.  Cannabis reduces opioid dose in the treatment of chronic non-cancer pain. , 2003, Journal of pain and symptom management.

[77]  R. Wise,et al.  Intravenous self‐administration of methamphetamine‐heroin (speedball) combinations under a progressive‐ratio schedule of reinforcement in rats , 2000, Neuroreport.

[78]  A. Polettini,et al.  The role of alcohol abuse in the etiology of heroin-related deaths. Evidence for pharmacokinetic interactions between heroin and alcohol. , 1999, Journal of analytical toxicology.

[79]  K. Robertson The European Monitoring Centre for Drugs and Drug Addiction , 1998 .

[80]  P. Beaune,et al.  Possible involvement of multiple cytochrome P450S in fentanyl and sufentanil metabolism as opposed to alfentanil. , 1997, Biochemical pharmacology.

[81]  H. Van Aken,et al.  Remifentanil: A Novel, Short-Acting, mu-Opioid , 1996, Anesthesia and analgesia.

[82]  R. Foltin,et al.  The cardiovascular and subjective effects of intravenous cocaine and morphine combinations in humans. , 1992, The Journal of pharmacology and experimental therapeutics.

[83]  K. Foley,et al.  Cocaine and morphine interaction in acute and chronic cancer pain , 1987, PAIN®.

[84]  K. Preston,et al.  Evaluation of mixtures of morphine and d-amphetamine for subjective and physiological effects. , 1986, Drug and alcohol dependence.

[85]  P. Schoeffler,et al.  Fentanyl pharmacokinetics in anaesthetized patients with cirrhosis. , 1982, British journal of anaesthesia.

[86]  H. Fields,et al.  Naloxone dose dependently produces analgesia and hyperalgesia in postoperative pain , 1979, Nature.

[87]  Unite Evaluations UNITED NATIONS OFFICE ON DRUGS AND CRIME-INDEPENDENT EVALUATION SECTION , 2020 .

[88]  G. Pasternak,et al.  Novel Synthetic Opioids and Overdose Deaths: Tip of the Iceberg? , 2018, Neuropsychopharmacology.

[89]  Rachael Rzasa Lynn,et al.  Naloxone dosage for opioid reversal: current evidence and clinical implications , 2018, Therapeutic advances in drug safety.

[90]  J. V. van Amsterdam,et al.  The Misuse of Prescription Opioids: A Threat for Europe? , 2015, Current drug abuse reviews.

[91]  T. Atkinson Interactions between Pain Medications and Illicit Street Drugs , 2014 .

[92]  M. Farré,et al.  [Abuse-related adverse drug reactions and abuse deterrent formulations]. , 2013, Medicina clinica.

[93]  S. Jortani,et al.  Handbook of Drug Interactions , 2012, Humana Press.

[94]  K. Bettinardi-Angres,et al.  NON-MEDICAL USE OF PRESCRIPTION DRUGS , 2012 .

[95]  A. Jatoi,et al.  A systematic compilation of reports published on opioid-related problems. , 2011, Journal of opioid management.

[96]  M. Meyer,et al.  Qualitative studies on the metabolism and the toxicological detection of the fentanyl-derived designer drugs 3-methylfentanyl and isofentanyl in rats using liquid chromatography–linear ion trap–mass spectrometry (LC-MSn) , 2011, Analytical and Bioanalytical Chemistry.

[97]  Howard S. Smith,et al.  Opioid metabolism. , 2009, Mayo Clinic proceedings.

[98]  Jos H Beijnen,et al.  Pharmacokinetics and pharmacokinetic variability of heroin and its metabolites: review of the literature. , 2006, Current clinical pharmacology.

[99]  S. Ferrara,et al.  Fatality due to fentanyl-cocaine intoxication resulting in a fall , 2005, International Journal of Legal Medicine.

[100]  E. Kharasch,et al.  Metabolism of alfentanil by cytochrome P 4503 A ( CYP 3 A ) enzymes , 2004 .

[101]  L. Raymon,et al.  Handbook of Drug Interactions , 2004, Forensic Science and Medicine.

[102]  S. Hemby,et al.  Synergistic elevations in nucleus accumbens extracellular dopamine concentrations during self-administration of cocaine/heroin combinations (Speedball) in rats. , 1999, The Journal of pharmacology and experimental therapeutics.

[103]  J. Boscarino,et al.  Substance Abuse and Rehabilitation Dovepress Opioid-use Disorder among Patients on Long-term Opioid Therapy: Impact of Final Dsm-5 Diagnostic Criteria on Prevalence and Correlates , 2022 .